Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

BRAF V600E mutation in biliary proliferations associated with α1 -antitrypsin deficiency.

Angkathunyakul N, Rosini F, Heaton N, Foskett P, Quaglia A.

Histopathology. 2017 Feb;70(3):485-491. doi: 10.1111/his.13083. Epub 2016 Nov 15.

PMID:
27627051
2.

BRAF V600E mutational status in bile duct adenomas and hamartomas.

Pujals A, Bioulac-Sage P, Castain C, Charpy C, Zafrani ES, Calderaro J.

Histopathology. 2015 Oct;67(4):562-7. doi: 10.1111/his.12674. Epub 2015 Mar 31.

PMID:
25704541
3.

BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.

Goeppert B, Frauenschuh L, Renner M, Roessler S, Stenzinger A, Klauschen F, Warth A, Vogel MN, Mehrabi A, Hafezi M, Boehmer K, von Deimling A, Schirmacher P, Weichert W, Capper D.

Mod Pathol. 2014 Jul;27(7):1028-34. doi: 10.1038/modpathol.2013.206. Epub 2013 Dec 6.

4.

BRAF V600E mutations in bile duct adenomas.

Pujals A, Amaddeo G, Castain C, Bioulac-Sage P, Compagnon P, Zucman-Rossi J, Azoulay D, Leroy K, Zafrani ES, Calderaro J.

Hepatology. 2015 Jan;61(1):403-5. doi: 10.1002/hep.27133. Epub 2014 May 19. No abstract available.

PMID:
24634053
5.

Cholangiocarcinoma in two siblings with emphysema and alpha-1-antitrypsin deficiency.

Parham DM, Paterson JR, Gunn A, Guthrie W.

Q J Med. 1989 Apr;71(264):359-67.

PMID:
2556731
6.

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.

Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C.

Gut. 2003 May;52(5):706-12.

7.

Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Wang Y, Hong Y, Li M, Long J, Zhao YP, Zhang JX, Li Q, You H, Tong WM, Jia JD, Huang J.

PLoS One. 2013 Dec 13;8(12):e82426. doi: 10.1371/journal.pone.0082426. eCollection 2013.

8.
9.

Cholangiocarcinoma with intraductal tubular growth pattern versus intraductal papillary growth pattern.

Tsukahara T, Shimoyama Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nakamura S, Nagino M.

Mod Pathol. 2016 Mar;29(3):293-301. doi: 10.1038/modpathol.2015.152. Epub 2016 Jan 15.

10.

Intrahepatic cholangiocarcinoma arising in chronic advanced liver disease and the cholangiocarcinomatous component of hepatocellular cholangiocarcinoma share common phenotypes and cholangiocarcinogenesis.

Xu J, Sasaki M, Harada K, Sato Y, Ikeda H, Kim JH, Yu E, Nakanuma Y.

Histopathology. 2011 Dec;59(6):1090-9. doi: 10.1111/j.1365-2559.2011.04058.x.

PMID:
22175889
11.

Cholangiocarcinoma arising in bile duct adenoma with focal area of bile duct hamartoma.

Hasebe T, Sakamoto M, Mukai K, Kawano N, Konishi M, Ryu M, Fukamachi S, Hirohashi S.

Virchows Arch. 1995;426(2):209-13.

PMID:
7757293
12.

Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.

Akiba J, Nakashima O, Hattori S, Tanikawa K, Takenaka M, Nakayama M, Kondo R, Nomura Y, Koura K, Ueda K, Sanada S, Naito Y, Yamaguchi R, Yano H.

Am J Surg Pathol. 2013 Apr;37(4):496-505. doi: 10.1097/PAS.0b013e31827332b0.

PMID:
23388123
13.

Primary liver carcinoma in genetic hemochromatosis reveals a broad histologic spectrum.

Morcos M, Dubois S, Bralet MP, Belghiti J, Degott C, Terris B.

Am J Clin Pathol. 2001 Nov;116(5):738-43.

PMID:
11710692
14.

Bile duct adenoma and von Meyenburg complex-like duct arising in hepatitis and cirrhosis: pathogenesis and histological characteristics.

Aishima S, Tanaka Y, Kubo Y, Shirabe K, Maehara Y, Oda Y.

Pathol Int. 2014 Nov;64(11):551-9. doi: 10.1111/pin.12209. Epub 2014 Oct 20.

PMID:
25329860
15.

Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E.

Mesteri I, Bayer G, Meyer J, Capper D, Schoppmann SF, von Deimling A, Birner P.

Mod Pathol. 2014 Jan;27(1):135-44. doi: 10.1038/modpathol.2013.126. Epub 2013 Jul 26.

16.

Different carcinogenic process in cholangiocarcinoma cases epidemically developing among workers of a printing company in Japan.

Sato Y, Kubo S, Takemura S, Sugawara Y, Tanaka S, Fujikawa M, Arimoto A, Harada K, Sasaki M, Nakanuma Y.

Int J Clin Exp Pathol. 2014 Jul 15;7(8):4745-54. eCollection 2014.

17.

Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.

Schlitter AM, Born D, Bettstetter M, Specht K, Kim-Fuchs C, Riener MO, Jeliazkova P, Sipos B, Siveke JT, Terris B, Zen Y, Schuster T, Höfler H, Perren A, Klöppel G, Esposito I.

Mod Pathol. 2014 Jan;27(1):73-86. doi: 10.1038/modpathol.2013.112. Epub 2013 Jul 5.

18.

Mutation analysis and copy number changes of KRAS and BRAF genes in Taiwanese cases of biliary tract cholangiocarcinoma.

Huang WC, Tsai CC, Chan CC.

J Formos Med Assoc. 2017 Jun;116(6):464-468. doi: 10.1016/j.jfma.2016.07.015. Epub 2016 Oct 10.

19.

Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract.

Abraham SC, Lee JH, Hruban RH, Argani P, Furth EE, Wu TT.

Hum Pathol. 2003 Sep;34(9):902-10.

PMID:
14562286
20.

Alpha-1-antitrypsin-positive "signet-ring" bile duct adenoma in a patient with M(MALTON) mutation.

Gambarotti M, Medicina D, Baronchelli C, Bercich L, Bonetti F, Facchetti F.

Int J Surg Pathol. 2008 Apr;16(2):218-21. doi: 10.1177/1066896907306968.

PMID:
18417685

Supplemental Content

Support Center